C Kent Osborne
Overview
Explore the profile of C Kent Osborne including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
154
Citations
13965
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Veeraraghavan J, De Angelis C, Gutierrez C, Liao F, Sabotta C, Rimawi M, et al.
Adv Exp Med Biol
. 2025 Jan;
1464():495-525.
PMID: 39821040
HER2-positive (+) breast cancer is an aggressive disease with poor prognosis, a narrative that changed drastically with the advent and approval of trastuzumab, the first humanized monoclonal antibody targeting HER2....
2.
Lei J, Dobrolecki L, Huang C, Srinivasan R, Vasaikar S, Lewis A, et al.
bioRxiv
. 2024 Dec;
PMID: 39713418
Combination chemotherapy remains essential for clinical management of triple-negative breast cancer (TNBC). Consequently, responses to multiple single agents cannot be delineated at the single patient level, even though some patients...
3.
Xu L, Peng F, Luo Q, Ding Y, Yuan F, Zheng L, et al.
Cell
. 2024 Oct;
187(25):7248-7266.e34.
PMID: 39419025
Chemotherapy is often combined with immune checkpoint inhibitor (ICIs) to enhance immunotherapy responses. Despite the approval of chemo-immunotherapy in multiple human cancers, many immunologically cold tumors remain unresponsive. The mechanisms...
4.
Fu X, Pereira R, Liu C, De Angelis C, Shea M, Nanda S, et al.
Cell Rep
. 2023 Jul;
42(8):112821.
PMID: 37467106
Aberrant activation of the forkhead protein FOXA1 is observed in advanced hormone-related cancers. However, the key mediators of high FOXA1 signaling remain elusive. We demonstrate that ectopic high FOXA1 (H-FOXA1)...
5.
Veeraraghavan J, Gutierrez C, De Angelis C, Davis R, Wang T, Pascual T, et al.
Clin Cancer Res
. 2023 May;
29(16):3101-3109.
PMID: 37195235
Purpose: Clinical trials reported 25% to 30% pathologic complete response (pCR) rates in HER2+ patients with breast cancer treated with anti-HER2 therapies without chemotherapy. We hypothesize that a multiparameter classifier...
6.
Harvey J, Clark G, Osborne C, Allred D
J Clin Oncol
. 2023 Feb;
41(7):1331-1338.
PMID: 36827742
Purpose: Immunohistochemistry (IHC) is a newer technique for assessing the estrogen receptor (ER) status of breast cancers, with the potential to overcome many of the shortcomings associated with the traditional...
7.
Arpino G, de la Haba Rodriguez J, Ferrero J, De Placido S, Osborne C, Klingbiel D, et al.
Clin Cancer Res
. 2023 Jan;
29(8):1468-1476.
PMID: 36716289
Purpose: In PERTAIN's primary analysis (31 months' median follow-up), adding pertuzumab to trastuzumab and an aromatase inhibitor (AI) with/without chemotherapy significantly improved progression-free survival (PFS) in patients with previously untreated...
8.
Petrosyan V, Dobrolecki L, Thistlethwaite L, Lewis A, Sallas C, Srinivasan R, et al.
iScience
. 2023 Jan;
26(1):105799.
PMID: 36619972
Although systemic chemotherapy remains the standard of care for TNBC, even combination chemotherapy is often ineffective. The identification of biomarkers for differential chemotherapy response would allow for the selection of...
9.
Anurag M, Jaehnig E, Krug K, Lei J, Bergstrom E, Kim B, et al.
Cancer Discov
. 2022 Aug;
12(11):2586-2605.
PMID: 36001024
Significance: Proteogenomic analysis of triple-negative breast tumors revealed a complex landscape of chemotherapy response associations, including a 19q13.31-33 somatic deletion encoding genes serving lagging-strand DNA synthesis (LIG1, POLD1, and XRCC1),...
10.
Acs B, Leung S, Kidwell K, Arun I, Augulis R, Badve S, et al.
Mod Pathol
. 2022 Jun;
35(10):1362-1369.
PMID: 35729220
Ki67 has potential clinical importance in breast cancer but has yet to see broad acceptance due to inter-laboratory variability. Here we tested an open source and calibrated automated digital image...